Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Truxima (rituximab) for the Treatment of Cancer

Drug (Brand / Generic)

Truxima / rituximab

Company / Licensee

Celltrion Healthcare / Mundipharma

Therapy Class

Monoclonal antibody (mAb)

Current Indications

Non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis and microscopic polyangiitis

Market Sector

Oncology

Development Status

Approved in Europe, South Korea and Japan
Expand

Go Top